Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma

Blood Cancer J. 2023 Oct 13;13(1):158. doi: 10.1038/s41408-023-00929-0.

Authors

Surbhi Sidana^#¹, Hitomi Hosoya², Alexandria Jensen³, Lawrence Liu⁴, Anmol Goyal², Vanna Hovanky², Bita Sahaf^{2

5}, Sushma Bharadwaj², Theresa Latchford², Sally Arai², Sheryl Leahy⁴, Matthew Mei⁴, Lihua E Budde⁴, Lori S Muffly², Matthew J Frank², Saurabh Dahiya², Myo Htut⁴, David Miklos², Murali Janakiram^#⁴

Affiliations

¹ Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, USA. surbhi.sidana@stanford.edu.
² Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, USA.
³ Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA.
⁴ City of Hope Cancer Center, Duarte, CA, USA.
⁵ Cancer Correlative Science Unit, Stanford University, Stanford, CA, USA.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

B-Cell Maturation Antigen
Bendamustine Hydrochloride
Cell- and Tissue-Based Therapy
Cyclophosphamide / therapeutic use
Humans
Immunotherapy, Adoptive
Multiple Myeloma* / therapy
Receptors, Chimeric Antigen*

Substances

Receptors, Chimeric Antigen
Bendamustine Hydrochloride
B-Cell Maturation Antigen
fludarabine
Cyclophosphamide

Grants and funding

KL2 TR003143/TR/NCATS NIH HHS/United States